Poster
Dato-DXd
ESMO Asia 2025 | December 5-7, 2025
Lung Cancer
A multicenter, real-world study of treatment patterns and clinical outcomes of later-line therapy in Chinese patients with advanced non-small cell lung cancer harboring non-actionable genomic alterations (RECAP Study)
Hanxiao Chen
Poster
I-DXd
WCLC 2025 | September 6-9 2025
Lung Cancer
A phase 1b/2 study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer
Melissa Johnson
Poster
I-DXd
ESMO 2025 | October 17-21, 2025
Lung Cancer
A phase 1b/2 study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer
Jair Bar
Poster
I-DXd
ISPOR 2026 | May 17-20, 2026
Lung Cancer
An indirect treatment comparison of ifinatamab deruxtecan (I-DXd) versus real-world physicians’ choice of therapy in patients previously treated with at least 2 lines of therapy for extensive-stage small cell lung cancer
Jie Meng
Poster
T-DXd
WCLC 2025 | September 6-9 2025
Lung Cancer
Concordance of HER2 overexpression by IHC and ERBB2 gene amplification by NGS in lung cancer
Samrat Yeramaneni
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
Lung Cancer
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Toshihiko Doi
Poster
Dato-DXd
ACoP16 | October 18-21, 2025
Lung Cancer
Exposure-response analysis of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in patients with advanced or metastatic non-small cell lung cancer
Jaydeep Sinha
Poster
Dato-DXd
ELCC 2026 | March 25-28, 2026
Lung Cancer
Full device assessment of trophoblastic cell surface antigen 2 (TROP2) normalized membrane ratio (NMR) in non-small cell lung carcinoma (NSCLC) using a computational pathology algorithm in real-world laboratories
Fernando Lopez-Rios
Oral
HER3-DXd
JSMO 2026 | March 26-28, 2026
Lung Cancer
HERTHENA-PanTumor01: Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic solid tumors
Izuma Nakayama
Poster
Dato-DXd
ELCC 2026 | March 25-28, 2026
Lung Cancer
Identification of DXd sensitivity biomarkers and osimertinib-enhanced datopotamab deruxtecan (Dato-DXd) internalization as potential mechanisms for enhanced activity of Dato-DXd in preclinical models of EGFR-mutant non-small cell lung cancer
Matthew Sung
Pages: 1  2  3  4